Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

895

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Interventions

DRUG: Capivasertib
DRUG: Fulvestrant
DRUG: Palbociclib
DRUG: Ribociclib
DRUG: Abemaciclib

Sponsor

AstraZeneca